Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study

Villani, Alessia; Costa, Cláudia; Fabbrocini, Gabriella; Scalvenzi, Massimiliano

doi:10.1111/dth.15036

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this trial, the OR for patients treated with sonidegib was 81% ( n = 17; 95% CI 60–95%) including 6 (29%) patients with a complete response (CR). These observations are consistent with earlier findings from the long-term 30-month analysis of the pivotal phase II BOLT study and recently published 42-month analysis with an OR of 74.2% per investigator review using RECIST-criteria and the reported OR of 76.8% in a retrospective case series conducted in 13 patients ( 14 , 19 ).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

Herms

Baroudjian²,

Delyon³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of sonidegib has been reported. An observational, retrospective, single-centre study (PaSoS study) was conducted. The primary objective was to evaluate the efficacy of sonidegib for treatment of locally advanced basal cell carcinoma in a real-world setting. Secondary objectives included modalities of use, tolerability, tumour evolution, and management after discontinuation. A total of 21 patients treated with sonidegib were included from March 2018 to January 2021. The median follow-up was 18.7 months and median exposure 7.0 months. Objective response (OR) rate was 81.0% (n = 17) including 6 (29%) patients with a complete response (CR). Disease control rate was 100%. First tumour response was rapid, with a median time of 2.3 months. Nine (43%) patients underwent surgery after sonidegib discontinuation, and no relapse was observed. All the patients experienced at least 1 adverse event (AE). Muscle spasms were the most frequent AE (n = 14; 67%), followed by dysgeusia (n = 8; 38%) and alopecia (n = 12; 57%). The efficacy and safety profile of sonidegib in this first-to-date real-life trial are consistent with prior results. Overall, real-world evidence corroborated sonidegib efficacy and tolerability as a first-line treatment for locally advanced basal cell carcinoma.

show abstract

Section: Discussionsupporting

confidence: 92%

“…To date, several clinical cases have been published, demonstrating sonidegib’s rapid activity and great tolerance, but larger sample size clinical investigations are required to validate these findings in clinical practice ( 17 – 19 ). The current study is the first conducted in patients with laBCC treated with 200 mg in real life.…”

Section: Discussionmentioning

confidence: 99%

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

Herms

Baroudjian²,

Delyon³

et al. 2022

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head–neck region: A retrospective study

Abstract: Basal cell carcinoma (BCC) is the most commonly diagnosed human cancer, typically occurring in faired-skin subjects over 50 years old.Although it could occur in multiple locations, 80% of the patients pre-

Cited by 1 publication

References 9 publications

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

Contact Info

Product

Resources

About